Earnings
Niagen CEO Says A Joint Venture For Its Rare-Disease Drug Is 'Very Possible' In 2027
Rob Fried says "we have a tiger by the tail" in NB4168, as third-quarter net sales came in at $27.2 million.
Niagen Bioscience (NAGE) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Rob Fried says "we have a tiger by the tail" in NB4168, as third-quarter net sales came in at $27.2 million.
SEC Filings
Ingredient sales fell to $3.8 million from $6.9 million, and the CEO again called 2026 an investment year.